Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor 2.0

A topical collection in Cells (ISSN 2073-4409). This collection belongs to the section "Cell Signaling".

Viewed by 4680

Editors

Division of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
Interests: applied and experimental oncology; fibroblast growth factor receptor signaling; telomere maintenance mechanisms; alternative splicing; human and canine tumor cell models; novel therapeutic strategies; biomarkers
Special Issues, Collections and Topics in MDPI journals
Division of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
Interests: cellular and molecular tumor biology; in vitro models; colon adenomas and carcinomas; growth factor receptor signaling; therapy response, prognostic and predictive markers
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

Following the successful publication of the first Special Issue of “Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor”, we are very pleased to launch this new edition, which is dedicated to highlighting the recent translational research in this field, ranging from basic science to clinical studies.

Signaling by fibroblast growth factors (FGFs) and their receptors is an important part of the multilayered network of signal transduction in the cells of the human body, which requires a well-orchestrated interaction to ensure proper functionality. These protein family members of ligands and receptors are crucial for embryonic development and in the adult organism, but are dysregulated in the majority of malignant diseases. Research on FGFRs and related tyrosine receptor kinases in healthy and cancer cells has resulted in several mostly multi-target inhibitors, already in clinical trials or used as cancer drugs. However, the impact of FGFR signaling on the growth, survival and invasiveness of cancer cells and on healthy cells, driving angiogenesis and metastasis in a paracrine manner, are still not completely understood. Further knowledge may lead to the identification of the therapeutic targets and predictive markers needed for specific cancer therapy.

This Special Issue invites reviews and original papers covering translational research on FGFR signaling, with a strong emphasis on the improvement of knowledge for clinical application.

Dr. Klaus Holzmann
Dr. Brigitte Marian
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • FGFR
  • downstream signaling
  • targeted therapy
  • angiogenesis
  • tumor cell motility
  • tumor microenvironment
  • cancer progression
  • therapy resistance
  • cancer stem cells

Published Papers (2 papers)

2023

Jump to: 2022

14 pages, 2121 KiB  
Article
Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene
by Garima Dixit, Benjamin A. Pappas, Gourav Bhardwaj, Willow Schanz and Thorsten Maretzky
Cells 2023, 12(18), 2227; https://doi.org/10.3390/cells12182227 - 07 Sep 2023
Cited by 1 | Viewed by 946
Abstract
Functional analysis of somatic mutations in tumorigenesis facilitates the development and optimization of personalized therapy for cancer patients. The fibroblast growth factor receptor 2 (FGFR2) gene is frequently mutated in endometrial cancer (EC), but the functional implications of FGFR2 mutations in [...] Read more.
Functional analysis of somatic mutations in tumorigenesis facilitates the development and optimization of personalized therapy for cancer patients. The fibroblast growth factor receptor 2 (FGFR2) gene is frequently mutated in endometrial cancer (EC), but the functional implications of FGFR2 mutations in cancer development remain largely unexplored. In this study, we introduced a reliable and readily deployable screening method to investigate the effects of FGFR2 mutations. We demonstrated that distinct mutations in FGFR2 can lead to differential downstream consequences, specifically affecting a disintegrin- and metalloprotease 17 (ADAM17)-dependent shedding of the epidermal growth factor receptor (EGFR) ligand heparin-binding EGF-like growth factor (HB-EGF) and phosphorylation of mitogen-activated protein kinases (MAPKs). Furthermore, we showed that the distribution of mutations within the FGFR2 gene can influence their oncogenic effects. Together, these findings provide important insights into the complex nature of FGFR2 mutations and their potential implications for EC. By unraveling the distinct effects of different mutations, our study contributes to the identification of personalized treatment strategies for patients with FGFR2-mutated cancers. This knowledge has the potential to guide the development of targeted therapies that specifically address the underlying molecular alterations associated with FGFR2 mutations, ultimately improving patient outcomes in EC and potentially other cancer types characterized by FGFR2 mutations. Full article
Show Figures

Figure 1

2022

Jump to: 2023

22 pages, 1469 KiB  
Review
Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
by Peter Ellinghaus, Daniel Neureiter, Hendrik Nogai, Sebastian Stintzing and Matthias Ocker
Cells 2022, 11(19), 3180; https://doi.org/10.3390/cells11193180 - 10 Oct 2022
Cited by 9 | Viewed by 2636
Abstract
Inhibitors of fibroblast growth factor receptor (FGFR) signaling have been investigated in various human cancer diseases. Recently, the first compounds received FDA approval in biomarker-selected patient populations. Different approaches and technologies have been applied in clinical trials, ranging from protein (immunohistochemistry) to mRNA [...] Read more.
Inhibitors of fibroblast growth factor receptor (FGFR) signaling have been investigated in various human cancer diseases. Recently, the first compounds received FDA approval in biomarker-selected patient populations. Different approaches and technologies have been applied in clinical trials, ranging from protein (immunohistochemistry) to mRNA expression (e.g., RNA in situ hybridization) and to detection of various DNA alterations (e.g., copy number variations, mutations, gene fusions). We review, here, the advantages and limitations of the different technologies and discuss the importance of tissue and disease context in identifying the best predictive biomarker for FGFR targeting therapies. Full article
Show Figures

Figure 1

Back to TopTop